Insider · CIK 0001472357
Nikos Fountas
Files at EEFT (EURONET WORLDWIDE, INC.). First filing Dec 10, 2024, latest Dec 10, 2024.
In brief
Nikos Fountas files SEC Form 4 as CEO at EEFT (EURONET WORLDWIDE, INC.). Since Dec 10, 2024, Nikos Fountas has reported 0 open-market buys worth $0 and 1 open-market sell worth $2.2M, the latest filed on Dec 10, 2024.
A track record needs three past buys with six months of prices behind them; Nikos Fountas has 0, so none is measured yet.
The newest scored trade: sold $2.2M of EEFT on Dec 9, 2024, filed Dec 10, 2024, scored 60 (notable).
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
EEFT: EURONET WORLDWIDE, INC.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 60Notable | EURONET WORLDWIDE, INC. | $2.2M 21,479 shares | -29% | - |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Dec 9, 2024 | EEFT EURONET WORLDWIDE, INC. | 21,479 0.05% of outstanding | $2.2M | Dec 9, 2024 | none |
Transactions
Every row this insider has filed, 10 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Feb 26, 2026 | EEFT EURONET WORLDWIDE, INC. | AGrant or award Common Stock, par value $0.02 per share | +15,701 | $0.00 | $0 | 79,993 | Mar 2, 2026 |
| Dec 10, 2025 | EEFT EURONET WORLDWIDE, INC. | MOption exercise Common Stock, par value $0.02 per share | +16,341 | $74.72 | $1.2M | 80,049 | Dec 12, 2025 |
| Dec 10, 2025 | EEFT EURONET WORLDWIDE, INC. | FTax withholding Common Stock, par value $0.02 per share | -15,757 | $77.49 | $1.2M | 64,292 | Dec 12, 2025 |
| Dec 10, 2025 | EEFT EURONET WORLDWIDE, INC. | MOption exercise Employee Stock Option (right to buy)derivative | -16,341 | $0.00 | $0 | 0 | Dec 12, 2025 |
| Feb 25, 2025 | EEFT EURONET WORLDWIDE, INC. | AGrant or award Common Stock, par value $0.02 per share | +11,338 | $0.00 | $0 | 63,308 | Feb 27, 2025 |
| Dec 10, 2024 | EEFT EURONET WORLDWIDE, INC. | MOption exercise Employee Stock Option (right to buy)derivative | +33,488 | $104.18 | $3.5M | 33,488 | Dec 12, 2024 |
| Dec 9, 2024 | EEFT EURONET WORLDWIDE, INC. | MOption exercise Common Stock, par value $0.02 per share | +21,479 | $56.24 | $1.2M | 73,849 | Dec 10, 2024 |
| Dec 9, 2024 | EEFT EURONET WORLDWIDE, INC. | SOpen-market sale Common Stock, par value $0.02 per share | -10,128 | $103.13 | $1.0M | 63,721 | Dec 10, 2024 |
| Dec 9, 2024 | EEFT EURONET WORLDWIDE, INC. | SOpen-market sale Common Stock, par value $0.02 per share | -11,351 | $103.94 | $1.2M | 52,370 | Dec 10, 2024 |
| Dec 9, 2024 | EEFT EURONET WORLDWIDE, INC. | MOption exercise Employee Stock Option (right to buy)derivative | -21,479 | $0.00 | $0 | 0 | Dec 10, 2024 |
Questions about Nikos Fountas
Answered from the filings on this page, as of the latest one.
Is Nikos Fountas buying or selling?
Not in the last 12 months. Nikos Fountas's latest open-market trade on SEC Form 4 was sold $2.2M of EEFT on Dec 9, 2024.
How did Nikos Fountas's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Nikos Fountas has 0.
Where does Nikos Fountas file Form 4?
Nikos Fountas has filed Form 4 at EEFT (EURONET WORLDWIDE, INC.) as CEO, EFT EMEA Division. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.